|
Volumn 55, Issue 6, 2001, Pages 321-323
|
Predictors of protease inhibitor-associated adverse events
|
Author keywords
Adverse reactions; Protease inhibitors; Surveillance
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CD4 ANTIGEN;
EFAVIRENZ;
LAMIVUDINE;
PROTEINASE INHIBITOR;
RITONAVIR;
RITONAVIR PLUS SAQUINAVIR;
SAQUINAVIR;
STAVUDINE;
UNCLASSIFIED DRUG;
ZIDOVUDINE;
ADULT;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG SURVEILLANCE PROGRAM;
FEMALE;
FOLLOW UP;
HETEROSEXUALITY;
HIGH RISK PATIENT;
HOMOSEXUALITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INTRAVENOUS DRUG ABUSE;
LYMPHOCYTE COUNT;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
PRIORITY JOURNAL;
REGRESSION ANALYSIS;
RISK ASSESSMENT;
RISK FACTOR;
SIDE EFFECT;
|
EID: 0034960836
PISSN: 07533322
EISSN: None
Source Type: Journal
DOI: 10.1016/S0753-3322(01)00070-1 Document Type: Article |
Times cited : (13)
|
References (8)
|